FY2028 EPS Estimates for Genmab A/S Raised by William Blair

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at William Blair lifted their FY2028 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $4.06 per share for the year, up from their prior estimate of $4.02. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

A number of other analysts also recently commented on the company. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Truist Financial dropped their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Stock Performance

GMAB stock opened at $20.26 on Wednesday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The stock’s 50 day moving average price is $21.29 and its 200 day moving average price is $22.54. The firm has a market cap of $13.41 billion, a P/E ratio of 11.64, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC increased its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the period. Barclays PLC grew its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.